fbpx
Pipeline

ATA2271/ATA3271

Atara is developing a mesothelin-targeted autologous CAR T (ATA2271) for advanced mesothelioma and is also developing an off-the-shelf, allogeneic CAR T immunotherapy targeting mesothelin (ATA3271).

ATA2271/ATA3271

Program/Indication Preclinical Phase 1 Phase 2 Phase 3
ATA2271: Mesothelioma & other solid tumors
  • Target: Mesothelin
  • Technologies: CAR T PD-1 DNR; Novel CAR T 1XX co-stimulation
  • Autologous (ATA2271)
  • Mesothelin is expressed at high levels on the surface of cells in aggressive solid tumors including mesothelioma, triple-negative breast cancer, esophageal cancer, pancreatic cancer and non-small cell lung cancer
  • MSK investigator-sponsored Phase 1 study (NCT02414269) of a mesothelin-targeted CAR T immunotherapy is ongoing
  • ATA2271 Atara’s CAR T collaboration with MSK will focus on development of a next-generation, mesothelin-targeted CAR T using novel 1XX CAR signaling and PD-1 dominant negative receptor (DNR) checkpoint inhibition technologies.
ATA3271: Mesothelioma & other solid tumors
  • Target: Mesothelin
  • Technologies: CAR T PD-1 DNR; Novel CAR T 1XX co-stimulation
  • Off-the-shelf, allogeneic (ATA3271)
  • Mesothelin is expressed at high levels on the surface of cells in aggressive solid tumors including mesothelioma, triple-negative breast cancer, esophageal cancer, pancreatic cancer and non-small cell lung cancer
Program/Indication Phase
ATA2271: Mesothelioma & other solid tumors Phase 1
  • Target: Mesothelin
  • Technologies: CAR T PD-1 DNR; Novel CAR T 1XX co-stimulation
  • Autologous (ATA2271)
  • Mesothelin is expressed at high levels on the surface of cells in aggressive solid tumors including mesothelioma, triple-negative breast cancer, esophageal cancer, pancreatic cancer and non-small cell lung cancer
  • MSK investigator-sponsored Phase 1 study (NCT02414269) of a mesothelin-targeted CAR T immunotherapy is ongoing
  • ATA2271 Atara’s CAR T collaboration with MSK will focus on development of a next-generation, mesothelin-targeted CAR T using novel 1XX CAR signaling and PD-1 dominant negative receptor (DNR) checkpoint inhibition technologies.
ATA3271: Mesothelioma & other solid tumors Preclinical
  • Target: Mesothelin
  • Technologies: CAR T PD-1 DNR; Novel CAR T 1XX co-stimulation
  • Off-the-shelf, allogeneic (ATA3271)
  • Mesothelin is expressed at high levels on the surface of cells in aggressive solid tumors including mesothelioma, triple-negative breast cancer, esophageal cancer, pancreatic cancer and non-small cell lung cancer

ATA2271 – Autologous Mesothelin-Targeted
CAR T Program in Solid Tumors

ATA2271 – Autologous Mesothelin-Targeted CAR T Program in Solid Tumors

  • Mesothelin is an attractive target associated with aggressive solid tumors
  • Maintains ScFv that binds to mesothelin only above cancer threshold
  • Incorporates next-gen CAR T technologies
    • Novel 1XX costimulatory domain may offer greater persistence and more physiologic T cell signaling
    • PD-1 Dominant Negative Receptor (DNR) designed to provide intrinsic checkpoint inhibition and unlock the solid tumor microenvironment

ATA3271 – Off-the-Shelf,
Allogeneic Mesothelin CAR T

ATA3271 – Off-the-Shelf, Allogeneic Mesothelin CAR T

Next-Generation CAR T Technology

Our preclinical pipeline is rapidly expanding with novel technologies and next-generation, multi-targeted CAR T immunotherapies thanks to our collaborations with Moffitt Cancer Center and Memorial Sloan Kettering Cancer Center.
View Next-Generation CAR T